1. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives
- Author
-
Ausoni, Simonetta, Boscolo Rizzo, Paolo, Singh, Bhuvanesh, Da Mosto, Maria Cristina, Spinato, Giacomo, Tirelli, GIAN CARLO, Spinato, Roberto, Azzarello, Giuseppe, BOSCOLO RIZZO, Paolo, Ausoni, Simonetta, Boscolo Rizzo, Paolo, Singh, Bhuvanesh, Da Mosto, Maria Cristina, Spinato, Giacomo, Tirelli, GIAN CARLO, Spinato, Roberto, Azzarello, Giuseppe, and BOSCOLO RIZZO, Paolo
- Subjects
0301 basic medicine ,Oncology ,Human papillomavirus ,Cancer Research ,medicine.medical_specialty ,Head and neck cancer ,Squamous cell carcinoma ,Target therapy ,Tumor microenvironment ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,Intratumoral Genetic Heterogeneity ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Tumor Microenvironment ,Humans ,Medicine ,Genetic Predisposition to Disease ,Molecular Targeted Therapy ,Treatment resistance ,Protein Kinase Inhibitors ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Genetic Variation ,medicine.disease ,Head and neck squamous-cell carcinoma ,Gene Expression Regulation, Neoplastic ,Clinical trial ,Radiation therapy ,Human papillomaviru ,Cell Transformation, Neoplastic ,030104 developmental biology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Neoplasm Grading ,business ,Signal Transduction - Abstract
Despite improvements in functional outcomes attributable to advances in radiotherapy, chemotherapy, surgical techniques, and imaging techniques, survival in head and neck squamous cell carcinoma (HNSCC) patients has improved only marginally during the last couple of decades, and optimal therapy has yet to be devised. Genomic complexity and intratumoral genetic heterogeneity may contribute to treatment resistance and the propensity for locoregional recurrence. Countering this, it demands a significant effort from both basic and clinical scientists in the search for more effective targeted therapies. Recent genomewide studies have provided valuable insights into the genetic basis of HNSCC, uncovering potential new therapeutic opportunities. In addition, several studies have elucidated how inflammatory, immune, and stromal cells contribute to the particular properties of these neoplasms. In the present review, we introduce recent findings on genomic aberrations resulting from whole-genome sequencing of HNSCC, we discuss how the particular microenvironment affects the pathogenesis of this disease, and we describe clinical trials exploring new perspectives on the use of combined genetic and cellular targeted therapies.
- Published
- 2016
- Full Text
- View/download PDF